Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts.
In vivo production and systemic delivery of therapeutic antibodies by engineered cells might advantageously replace injection of purified antibodies for treating a variety of life-threatening diseases, including cancer, acquired immunodeficiency syndrome, and autoimmune diseases. We report here that skin fibroblasts retrovirally transduced to express immunoglobulin genes can be used for sustained long-term systemic delivery of cloned antibodies in immunocompetent mice. Importantly, no anti- idiotypic response against the ectopically expressed model antibody used in this study was observed. This supports the notion that skin fibroblasts can potentially be used in antibody-based gene/cell therapy protocols without inducing any adverse immune response in treated individuals.
Noël
D
D
Institut de Génetique Moléculaire, UMR 5535, CNRS, Montpellier, France.
Pelegrin
M
M
Brockly
F
F
Lund
A H
AH
Piechaczyk
M
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics* / Q000627:therapeutic use*; D000917:Antibody Formation / Q000235:genetics; D004195:Disease Models, Animal; D005347:Fibroblasts / Q000276:immunology*; D015316:Genetic Therapy; D006801:Humans; D007121:Immunocompetence; D051379:Mice / Q000276:immunology*; D012867:Skin / Q000166:cytology*
D000911:Antibodies, Monoclonal